RBC Capital maintains Axsome Therapeutics at Outperform, lowers price target to $273 from $295
RBC Capital maintained its Outperform rating for Axsome Therapeutics but reduced its price target from $295 to $273. This implies a 100.7% upside from the Nov 2 close of $136.01. Recent analyst price targets for the company range from $220 to $295.
How this was made
The 30-second read
Why it matters
Analyst target reduction may trigger short‑term price decline.
Market read
Target cut provides fresh guidance that could affect AXSM trading.
What to watch
Potential upcoming clinical trial results not reflected in the target.
Background
Axsome Therapeutics is a clinical‑stage biotech focused on CNS disorders.
Ticker impact
RBC Capital lowered its price target on Axsome Therapeutics to $273 from $295, a 7.5% decrease.
likely pressure as the market prices in the lower target
Target reduction signals reduced upside, prompting short‑term sell pressure.
Market effects
Minor impact on biotech sector sentiment.
Limited to US biotech stocks.
Low
Counterpoint
Target cut may be overly cautious; upside could remain if upcoming data beats expectations.
Key entities
- companyAxsome Therapeutics
Biotech firm developing treatments for neurological diseases.
- analystRBC Capital
Equity research firm providing coverage on AXSM.
